GlobeNewswire

BBS Interim Report H1/2019

Share

BBS-Bioactive Bone Substitutes Plc (BBS) Interim Report January 1th  – June 30th 2019 (unaudited)

January-June shortly (comparison season 1-6/2018)

  • Updates as required by the new Medical Device Regulation (MDR 2017/745) must be implemented by May 2020
  • Validation of the production steps of the ARTEBONE® -final product is almost done, the final step of the validation of sterilization is under way
  • For the final product has its own customized dosing syringe completed and validated
  • Syringe filling equipment has been completed and validated for production
  • An additional large animal test proposed by the authorities is under way
  • The directed issue in Sweden resulted 215 new shareholders and about EUR 300.000 capital was received
  • The company’s investment and working capital loans have been restructured
  • Ernst & Young Oy was elected as a company’s auditor and KHT Jari Karppinen as the principal auditor
  • The company had no net sales during the period under review
  • The cash flow from operations was EUR 0,786 (1,153) million
  • BBS’s cash assets on 30th June 2019 was EUR 0,878 (2,270) million

Key financial figures

(1000) EUR 1-6/2019 1-6/2018 1-12/2018
Other operating income 29 *2 237 *2 262
Personnel expenses 350 356 670
Depreciation and impairments 112 112 229
Other operating expenses 340 588 757
Profit (Loss) of the period -809 -1 076 -447
Cash flow from business operations -786 -1 153 -1 701
Equity ratio % 34,6 42,8 39,6
Earnings per share € -0,16 -21 -0,076
The number of the shares at the end of the period 5 090 520 5 090 520 5 090 520
The average number of the shares during the period 5 090 520 4 904 136 4 998 094

*Includes EUR 2,22 million of the accord accorded to loans during 2018

(1000) EUR 06/30/2019 06/30/2018 12/31/2018
Cash and securities 878 2 270 1 685
Equity 3 558 5 061 4 417
Equity and liability total 10 298 11 816 11 156

The equity ratio = equity/equity and liabilities total
Earnings per share = earnings for the period/the average number of the shares during the period

Guidance for 2019
For the year 2019, substantial net sales are not expected to be generated. CE marking will not to be obtained during 2019.

Outlook for 2020
BBS will perform additional animal studies and drive forward the CE marking process of the first product and launch sales and marketing preparations.

Pekka Jalovaara, CEO

BBS-Bioactive Bone Substitutes Plc (BBS) is a growing Finnish company that has developed a new bone implant, medical device, for treating of bone traumas, bone losses and bone defects. The company has the headquarters and quality control laboratory in Oulu and the EU-certified production facility at Reisjärvi. The company has a history of over 15 years, during which time the company has developed product and production methods, performed required preclinical and clinical tests, and established a manufacturing line and a quality system for commercial production. The product development phase of a company like BBS is typically 10-15 years and BBS has not been able to fall below this, especially when this is a brand-new product at the interface between a medical device and a medicinal product.

Our company still has no turnover, but the CE marking and FDA approval processes required for the product’s marketing authorization are currently under way. Sales are expected to begin no later than next year as soon as the CE marking is received. Until now, BBS has been a product development company but is now heading for marketing and sales. Sales are expected to start in the Nordic countries and a few Central European countries, while investing heavily in partners.

ARTEBONE® product contains natural bone hard component, tricalcium phosphate mineral granules, as well as proteins including the bone growth factors that are extracted from reindeer bone. The product resorbs from the trauma when it heals. Currently there are products with only one of these components, but BBS has managed to combine these two. Our first product is a ready-to-use paste in the syringe so there is no need to make any mixing on the operating table, which is typical for competing products. ARTEBONE® product is based on its ingredients comparable to bank bone or human DBM (Demineralized Bone Matrix) products. DBM products have been found to poorly induce the formation of new bone. In addition, the quality of human-derived products may vary greatly depending on the age and health of the donor. The reindeer bone protein extract in ARTEBONE® is very homogeneous because bones from about 70 reindeer are used on one batch. Reindeer bone protein extract has been found safe in preclinical trials and no human viral diseases can be transmitted to patients. In clinical trial, ARTEBONE® has proven to be safe and functional.

Based on the studies carried out, the ARTEBONE® product can in future replace the most common currently used own bone grafts in the treatment of bone problems. This brings significant saving to the society, hospitals and patients. Own bone graft needs to be taken from your own body, typically from the iliac crest and this means additional surgery that takes time up to an hour. Surgical harvesting of bone also involves the risk of complications. With ARTEBONE® only one surgery is needed instead of two. Therefore, the hospitalization time is shortened, and the patient recovers more quickly.

Furthermore, our product is ecological because we use renewable materials in our premium products to promote people’s health.

Our first short-term goal is to get marketing approvals and to open sales in the Nordic countries and Europe.  One of our main goals is to find a big partner to ensure global access to the market. Large companies in the industry do not do their own product development; instead they observe the small product development companies.


FINANCIAL REVIEW 1th January – 30th June, 2018

Overall

BBS owns 100% of the subsidiary Bio Bones Oy, which owns the real estate for production in Reisjärvi. Bio Bones has no other business.

Operating income and development costs

BBS did not have any significant net sales during the review period and the corresponding period of the previous year. In other income the Tekes decision not to collect old product development loans of EUR 2,22 million has been recorded.

Financing and investments

The company’s cash assets at 30th June 2019 were EUR 0,88 (2,27) million. The company estimates that the current funding will be sufficient through austerity measures approximately one year after the date of this release.

The groups cash flow from operations was EUR -0,79 (-1,15) million in the review period.

Acquisitions and directed share issues

No acquisitions were made during the review period.

In June 2019 a directed share issue was held in Sweden. The offer dealt maximum of 509 000 new shares, circa 10% of present number of shares in the Company, for subscription by investors on the swedish market. The company organized a directed share issue in Sweden on 17th – 30th June 2019. The reason for the deviation from shareholder’s preference was to expand the company’s shareholder base in Sweden and to increase trading volume. The result was not yet clear during the review period.

Balance sheet

The consolidated balance sheet total on 30th June 2019 was EUR 10,30 (11,82) million. On the 30th June 2019 the company had a short-term debts EUR 1,37 (0,53) million, long-term loans to financial institutions EUR 5,37 (6,22) million, capital loans of EUR 0,18 (0,18) million. Financial income and expenses amounted to EUR -0,05 (-0,05) million.

The company’s investment and working capital loans amounts of EUR 641 668 and EUR 277 690 were renegotiated in June 2019. The loans would have fallen due in 2019 and 2020. Repayments on renewed loans begin at December 31th 2019 and end at December 31th 2024. The loan period is 5 year in equal installments every 6 months. The arrangement will significantly reduce the debt service burden.

During the review period no capitalized and product investments have been made in balance sheet.

Equity

Equity on 30th June 2019 was EUR 3,56 (5,06) million. In the financial statement at December 2018, the shareholders equity was EUR 4,42 million.

Staff and administration

The number of employees was 12 at the end of review period on 30th June 2019. Members of the board were Jarmo Halonen (chairman), Ilkka Kangasniemi, Auvo Kaikkonen, Tomi Numminen, Pekka Jalovaara and Hannu Säynäjäkangas. Pekka Jalovaara is acting as the CEO.

The annual general meeting 2019

The annual general meeting (AGM) of BBS was held in Oulu on 5th April 2019.

The AGM approved the financial statements for 2018 and discharged the members of the board of directors and the CEO from liability. The AGM decided, in accordance with the proposal of the board of directors, that no dividend be paid for the financial year 2018 and that the loss for the financial year is recorded in the profit/loss account.

The AGM approved the remuneration of board members for EUR 500 and for the chairman EUR 750 per meeting.

The AGM decided that a reasonable fee would be paid to the auditor in accordance with the invoice approved by the company. Auditing society Ernst&Young Oy was elected as the auditor of BBS, with KHT Juhani Rönkkö as the principal auditor.

Share-based incentive plan

The company has a valid stock option program for 2012 approved by the AGM in 18th July 2012. The board of directors has decided on options for the 2th January 2013 as authorized by the AGM. Options have been issued to key personnel and by each option can subscribe for one share at the price of one euro until 31th December 2019. The board of directors, on 9th January 2018, continued the subscribe period until 31th December 2023. Stock options may be issued up to 170 000 new shares and this has no perceptible impact on the earnings per share.

Risks and uncertainties

Debt accord 2018 and investment and working capital loans restructuring in June 2019 and directes share issue in Sweden have lowered the near future financial risk. The European Commission’s manual on medical devices reduced the risk associated with the classification of ARTEBONE®. According to the company’s management, there are no significant changes in the risks and uncertainties associated with the business of BBS during the first half of 2019.

There are significant risks and uncertainties associated with product development and commercialization that are beyond the control of the company, such as regulatory actions, regulatory changes and market willingness to receive a new product. Capitalization and capitalization of confirmed losses is not certain. Adequacy of funding is associated with uncertainties that may delay obtaining a marketing authorization.

Shares and shareholders

The BBS’s market capitalization at the end of the review period of outside the company 30th June 2019 was EUR 15,8 million. The closing price of the share on 30th June 2019 was EUR 3,10. The highest price for the review period was EUR 3,75 and the lowest was EUR 2,06.

BBS had 1025 registered shareholders and 5 090 520, according to a register of shareholders dated 30th June 2019.

The BBS’s board of directors and the CEO held 30th June 2019 total of 543 650 (543 650) shares including shares held through controlled companies, i.e. 10,7% of the company’s shares. Information about the company’s insider trading in the company’s shares is published on the company’s website.

Event after the review period

Ernst & Young has acted as the company’s auditor and KHT Juhani Rönkkö as the principal auditor, who will be employed by another company. The new auditor elected by the Board of Directors from 1th September 2019 is Ernst & Young Oy and KHT Jari Karppinen as the principal auditor.

The evaluators of the UK Notified Body, involved in the approval process of  our product, with whom agreement was reached on the approval path, apparently moved to other tasks possible related to Brexit. A new reviewer, appointed by Notified Body, suggested that the large animal study should have had one additional control group associated with evaluation of medicinal effect of bone protein exctract, i.e. classification of ARTEBONE. We would have been able to challenge this proposal by discussing with UK competent authorities controlling Notified Body, but it was no longer possible this year due to Brexit, because Notified Body was already registered in EU, Amsterdam. Therefore, there was no other option but to repeat the animal study. The animals were operated in August 2019 and the three-week follow-up results are expected to be completed in February 2020. The CE-mark application will be filed with these results and complete it later with 8 and 12 weeks results.

The subscription period for the directed share issue to Sweden expired June 30th 2019. On July 1th 2019 the Board of Directors approved the subscriptions and the subscribed shares were transferred to the book-entry account of subscribers on July 10th 2019. A total of 215 new shareholders subscribed for a total of 114 300 new shares. The share issue resulted in a dilution of approximately two percent in the number of shares and voting rights. The company’s total number of shares is 5 204 820 after the registration (July 5th 2019) of new shares.

Half-year accounting principles

The half-yearly review has been prepared in accordance with the Finnish Accounting Act and rules of the First North marketplace. Figures for the half-yearly review are unaudited.

Financial information 2020

The financial statement bulletin for January-December 2019 will be published on 20th March 2020, at 9 am. Interim Report H1/2020 will be released in August 31th 2020 at 9 am.

In Oulu August 30, 2019
BBS-Bioactive Bone Substitutes Plc
Board of Directors

For more information:

Pekka Jalovaara, CEO,

puh. 050 5529275, e-mail: pekka.jalovaara@bbs-artebone.fi

Hannu Säynäjäkangas, CFO,

puh. 040 5021092, e-mail: hannu.saynajakangas@bbs-artebone.fi

Certified Advisor:

Stockholm Certified Advisers AB, p. +46 70 5516 729

DISTRIBUTION:

Nasdaq Helsinki Oy

Nasdaq Stockholm AB

Key media

www.bbs-artebone.fi

This is information that BBS-Bioactive Bone Substitutes Plc is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on 30th August 2019 at 12 :00 am (UTC ).

BBS-Bioactive Bone Substitutes Plc is the health technology company operating since 2003. Before that there was a background of seven years of product development in the University of Oulu. We have developed a new product for healing of difficult bone fractures and for solving the problems in bone healing. Our mission is to offer new generation medicinal products for the orthopedic surgery. The research and development in the field of medicine requires perseverance and courage to develop new things.  We have over 20 years of expertise in this. Our operations are characterized by top expertise, innovativeness and dedicated and committed employees. The ARTEBONE ®product is ready and the application process for the CE-mark has been initiated. BBS is the company having its headquarters in Oulu. We have our own production plant located in Reisjärvi and it is approved by FIMEA. More information: www.bbs-artebone.fi.

ATTACHMENTS:

Financial Statement 30th June 2019
Cash Flow Statement 30th June 2019
Statement of changes in equity

Distribution: NASDAQ and key media


BBS-Bioactive Bone Substitutes Plc
     
CONSOLIDATED INCOME STATEMENT 1.1.-30.6.2019 1.1.-30.6.2018 1.1.-31.12.2018
             
 Other operating income 29 050,60 2 237 121,94 2 262 011,03
 Materials and services      
   Raw material and consumables      
     Purchase during the period -6 996,90 -57 557,54 -58 302,16
     External services -29 399,36 -46 912,67 -69 956,73
   Raw materials and services total -36 396,26 -104 470,21 -128 258,89
 Personnel expenses        
   Wages and salaries -301 676,59 -309 625,69 -576 744,28
   Social security expenses      
     Pension expenses      -41 883,80 -44 176,05 -84 065,19
     Other personnel expenses -6 159,02 -2 577,59 -9 026,53
 Personnel expenses total -349 719,41 -356 379,33 -669 836,00
 Depreciation and amortization      
   Depreciation according to plan -112 388,67 -112 241,02 -229 029,43
   Impairment of non-current assets 0,00 0,00 0,00
   Depreciation and amortization total -112 388,67 -112 241,02 -229 029,43
 Other operating expenses -339 542,53 -588 043,76 -757 410,10
 OPERATING PROFIT (LOSS) -808 996,27 1 075 987,62 477 476,61
 Financial income and expenses      
   Other interest income and other financing income      
     From others   0,18 1,65 1,80
   Other interest and financial expenses      
     To others   -50 050,03 -51 389,91 -97 638,60
 Financial income and expenses total -50 049,85 -51 388,26 -97 636,80
 PROFIT (LOSS) BEFORE APPROPRIATIONS AND TAXES -859 046,12 1 024 599,36 379 839,81
 PROFIT (LOSS) OF THE FINANCIAL PERIOD -859 046,12 1 024 599,36 379 839,81


BBS-Bioactive Bone Substitutes Plc      
CONSOLIDATED BALANCE SHEET 30.6.2019 30.6.2018 31.12.2018
           
 ASSETS      
           
 NON-CURRENT ASSETS      
 Intangible assets      
   Development expenditure 7 532 827,55 7 532 827,55 7 532 827,55
   Other Intangible assets 396 271,93 470 306,35 433 289,14
   Intangible assets total 7 929 099,48 8 003 133,90 7 966 116,69
 Tangible assets      
   Land and water areas 83 719,00 83 719,00 83 719,00
   Buildings and structures 534 920,50 575 183,34 554 321,76
   Machinery and equipment 739 027,62 812 793,14 773 860,95
   Tangible assets total 1 357 667,12 1 471 695,48 1 411 901,71
 NON-CURRENT ASSETS TOTAL 9 286 766,60 9 474 829,38 9 378 018,40
           
 CURRENT ASSETS      
 Debtors      
   Short term      
     Other debtors 131 721,88 69 436,88 93 416,69
     Prepayments and accrued income 1 693,15 1 496,98 0,00
     Short term debtors total 133 415,03 70 933,86 93 416,69
   Debtors total 133 415,03 70 933,86 93 416,69
 Cash and equivalents 877 563,84 2 269 877,20 1 684 870,70
 CURRENT ASSETS TOTAL 1 010 978,87 2 340 811,06 1 778 287,39
           
 ASSETS TOTAL 10 297 745,47 11 815 640,44 11 156 305,79


BBS-Bioactive Bone Substitutes Plc      
CONSOLIDATED BALANCE SHEET 30.6.2019 30.6.2018 31.12.2018
           
 EQUITY AND LIABILITIES      
           
 CAPITAL AND RESERVES      
   Equity      
     Share capital 80 000,00 27 984,01 80 000,00
   Equity total 80 000,00 27 984,01 80 000,00
   Share premium account 1 394 957,01 1 394 957,01 1 394 957,01
   Other reserves      
     Invested non-restricted equity fund 11 337 847,26 11 337 847,26 11 337 847,26
     Other reserves total 11 337 847,26 11 337 847,26 11 337 847,26
   Retained earnings (loss) -8 396 062,95 -8 775 902,76 -8 775 902,76
   Profit (loss) of the period -859 046,12 1 024 599,36 379 839,81
 CAPITAL AND RESERVES TOTAL 3 557 695,20 5 061 500,87 4 416 741,32
           
CREDITORS      
 Long term      
   Capital loans 175 825,46 175 825,46 175 825,46
   Loans from credit institutions 5 191 297,00 6 048 145,33 5 633 425,33
   Long term loans total 5 367 122,46 6 223 970,79 5 809 250,79
 Short term      
   Loans from credit institutions 963 793,00 122 648,67 521 664,67
   Trade creditors 23 123,41 60 692,92 20 923,70
   Other creditors 11 959,16 731,40 13 485,30
   Accrual and referred income 374 052,24 346 095,79 374 240,01
   Short term creditors total 1 372 927,81 530 168,78 930 313,68
 CREDITORS TOTAL 6 740 050,27 6 754 139,57 6 739 564,47
           
 EQUITY AND LIABILITIES TOTAL 10 297 745,47 11 815 640,44 11 156 305,79

CASH FLOW STATEMENT

BBS-Bioactive Bone Substitutes Plc Concern      
       
[thousand euros] 1-6/2019 1-6/2018 2018
       
 Cash flow from business operations      
 Profit (loss) before extraordinary items -859 1025 380
 Adjustments      
 Scheduled depreciation and amortization  112 112 229
 financial income and expenses 50 51 98
 Other adjustments: Chord of loans 0 -2224 -2224
 other adjustments: Write-downs 0 0 0
Cash flow before changes in working capital -697 -1036 -1517
       
 Change in working capital      
 Changes in short-term non-interest-bearing receivables  Increase (-) / Decrease (+)  -40 -11 -33
 Changes in inventory Increase (-) / Decrease (+)  0 0 0
 Changes in short-term non-interest-bearing loans Increase (+) / Decrease (-) -25 -22 -45
 Cash flow from business operations before  financial items and taxes -712 -1069 -1595
       
 Interest paid and other financial expenses from business operations  74 84 106
 Interest received and other financial income from business operations  0 0 0
 Cash flow before extraordinary items -786 -1153 -1701
 Cash flow from business operations (A)  -786 -1153 -1701
       
Cash flow from investments      
 Investments in tangible and intangible goods  -21 -13 -34
 Investments in shares in subsidiaries 0 0 0
 Loans granted 0 0 0
 Cash flow from investments (B)  -21 -13 -34
       
Cash flow from financing      
 Rights issue  0 3501 3501
 Raised long-term loans 0 0 0
 Repayment of long-term loans  0 0 0
 Raised short-term loans  0 0 100
 Repayment of short-term loans  0 100 100
 Cash flow from financing (C)  0 3401 3385
       
Changes in funds (A+B+C) Increase (+)/Decrease (-)  -807 2235 1650
       
 Funds at the beginning of the financial period  1685 35 35
 Funds at the end of the financial period  878 2270 1685

Equity development

(1000 EUR) Share capital Share premium account Invested unrestricted equity fund Accu-mulated profits Profit (loss) of the financial period Equity Total
Equity 01/01/2019 80 1 395 11 338 -8 776 380 4417
Paid share issue            
Profit/loss of the previous financial year       380 -380  
Profit/loss of the financial period         -859 -859
Equity 08/30/2019 80 1 395 11 338  -8 396 -859 3558

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Norsk Hydro: Federal Court lifts one of two embargos on Alunorte’s deposit area DRS220.9.2019 23:06:00 CESTPress release

The Federal Court in Belém, Brazil, today, September 20, lifted the embargo on Alunortes new bauxite residue disposal (DRS2) under the civil lawsuit. Alunorte is still subject to an embargo on DRS2 imposed by the same court in a parallel criminal lawsuit, but Alunorte is expecting an extension of the civil decision to the criminal case shortly. Alunorte will continue utilizing the old bauxite residue disposal area (DRS1) until the DRS2 embargo under the criminal case is lifted. The decision to lift the DRS2 embargo in the civil case against Alunorte came after Ministério Público and Alunorte submitted a joint petition to the federal court on August 30, requesting the embargoes to be lifted. “This is an important step towards resuming installation and commissioning activities of the solid residue deposit DRS2. It is a state-of-the-art deposit system, the only sustainable and long-term solution for Alunorte’s operations. Alunorte is the foundation of the aluminium value chain in Para, an

Norsk Hydro: Den føderale domstolen løfter ett av to embargoer på Alunortes deponiområde DRS220.9.2019 23:06:00 CESTPressemelding

Den føderale domstolen i Belém, Brasil, løftet i dag, 20. september, embargoen på det nye avfallsdeponiet for bauksittrester (DRS2) i den sivilrettslige prosessen. Embargoen på DRS2 fra den samme domstolen i straffesaken er fortsatt gjeldende, men det er forventet at avgjørelsen i den sivile saken vil gjøres gjeldende i straffesaken innen kort tid. Alunorte vil fortsette å bruke det gamle avfallsdeponiet for bauksittrester (DRS1) til DRS2-embargoen i straffesaken er løftet. Beslutningen om å løfte DRS2-embargoen i den sivilrettslige saken mot Alunorte kom etter at Alunorte og Ministério Público den 30. august innga en felles anmodning til den føderale domstolen om å løfte DRS2-embargoene. - Dette er et viktig steg mot å gjenoppta installasjons- og igangsettingsaktivitetene ved det DRS2. Dette er et toppmoderne avfallssystem og er den eneste langsiktige og bærekraftige løsningen for Alunorte. Alunorte er fundamentet for aluminiumverdikjeden i delstaten Pará, og jeg setter stor pris på s

Invitation to the special and extraordinary shareholders' meetings20.9.2019 22:53:00 CESTPress release

Mechelen, Belgium; 20 September 2019, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) invites its shareholders to a special and extraordinary shareholders' meeting. On 14 July 2019, Galapagos NV (the "Company" or "Galapagos") announced that it entered into a collaboration with Gilead Sciences, Inc., Gilead Biopharmaceutics Ireland UC, and Gilead Therapeutics A1 Unlimited Company. In view hereof, Galapagos has the honor to invite its shareholders, warrant holders, directors, and statutory auditor to its special and extraordinary shareholders' meetings that will be held on Tuesday 22 October 2019 at 2:00 p.m. (CEST) at the Company's registered office. The items on the agenda of the special and extraordinary general meetings of shareholders include, amongst other things, the appointment of Mr. Daniel O'Day and Dr. Linda Higgins as directors of the Company, the approval of the issuance of two warrants for the benefit of Gilead Therapeutics A1 Unlimited Company, an

Invitation to the special and extraordinary shareholders' meetings20.9.2019 22:01:00 CESTPress release

Mechelen, Belgium; 20 September 2019, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) invites its shareholders to a special and extraordinary shareholders' meeting. On 14 July 2019, Galapagos NV (the "Company" or "Galapagos") announced that it entered into a collaboration with Gilead Sciences, Inc., Gilead Biopharmaceutics Ireland UC, and Gilead Therapeutics A1 Unlimited Company. In view hereof, Galapagos has the honor to invite its shareholders, warrant holders, directors, and statutory auditor to its special and extraordinary shareholders' meetings that will be held on Tuesday 22 October 2019 at 2:00 p.m. (CEST) at the Company's registered office. The items on the agenda of the special and extraordinary general meetings of shareholders include, amongst other things, the appointment of Mr. Daniel O'Day and Dr. Linda Higgins as directors of the Company, the approval of the issuance of two warrants for the benefit of Gilead Therapeutics A1 Unlimited Company, an

Notice of third quarter 2019 results and conference call20.9.2019 19:00:00 CESTPress release

Notice of third-quarter 2019 results and conference call Luxembourg, 20 September 2019 – Millicom will announce its third-quarter results for the period ending 30 September 2019, on 23 October 2019 at approximately 22:00 (Stockholm) / 21:00 (London) / 16:00 (Miami) via a press release. The company will host a conference call for the global financial community on 24 October 2019 at 15:00 (Stockholm) / 14:00 (London) / 09:00 (Miami). The conference call will be webcast at www.millicom.com Dial-in information: Please dial in 5-10 minutes before the scheduled start time to register your attendance. Dial-in numbers for the call are as follows: Sweden: +46 (0) 8 5069 2180 Luxembourg: +352 2786 0515 UK: +44 (0) 844 571 8892 US: +1 866 966 1396 The access code is: 9380844 Replay information: A replay of the call will be available for 7 days from 24 October 2019 at: UK: +44 (0) 333 300 9785 US: +1 (917) 677-7532 The access code is: 9380844 -END- For further information, please contact Press: Vi

DNO ASA: Mandatory Notification of Trade20.9.2019 17:05:00 CESTPress release

DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands, Ireland and Yemen. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Oslo, 20 September 2019 - DNO ASA, the Norwegian oil and gas operator, has today purchased 1,900,000 own shares at an average price of NOK 14.0326 per share. Following this transaction, DNO holds 50,700,000 own shares. -- For further information, please contact: Media: media@dno.no Investors: investor.relations@dno.no -- DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore l